MARKETWATCH PRESS RELEASE
April 23, 2012, 11:15 a.m. EDT
SAN DIEGO, Apr 23, 2012 (GlobeNewswire via COMTEX) – Tear Lab Corporation TEAR +5.39% CA:TLB +2.50%(“TearLab” or the “Company”) announced that, today at the American Society of Cataract and Refractive Surgery 2012 Annual Meeting in Chicago, IL, prominent LASIK surgeon, Dr. Eric Donnenfeld, presented an interim analysis from a multicenter study designed to determine the overall prevalence of normal and abnormal tear fluid osmolarity in the patient population of clinicians who use the Tear Lab(R) Osmolarity System.
Normal tear film is in homeostasis with blood osmolarity at a reference value of 290 mOsm/L, with a normal “homeostatic range” for tear osmolarity defined as 275 – 307 mosm/L. Hyper osmolarity is defined as a tear fluid osmolarity value in excess of the homeostatic range (greater or equal to 308 mosm/L) in one or both eyes, and is used as a benchmark of dry eye disease (“DED”).
The study involved 1,019 adult subjects (647 female, 372 male) from 16 sites across the United States and Europe. All patients in the study demonstrated at least three of the following nine binary symptoms: fluctuating vision, contact lens discomfort, light sensitivity, watery eyes, tired eyes, redness, burning, itching and sand or grit.
The overall incidence of hyper osmolarity amongst the study population was 43.4%. Importantly, of the 42.4% of subjects who reported symptoms of DED, just 47.7% actually had the disease while 52.3% had some other form of ocular irritation. Conversely, of the 57.6% of study subjects that were asymptomatic, 40.2% actually had mild-to-moderate DED while 59.8% were within the normal homeostatic range.
Dr. Donnenfeld commented, “It has long been recognized that patient symptoms do not correlate with DED or disease severity. These findings confirm that. Patients may be asymptomatic for DED, but still present with hyper osmolarity. The good news is that eye doctors now have an objective tool to assess tear film health. Identification of asymptomatic DED by performing Tear Lab Osmolarity testing is particularly important prior to contact lens wear and before LASIK or cataract surgery as a dysfunctional tear film may pose a health risk and/or negatively impact surgical outcomes.”
About Tear Lab Corporation
Tear Lab Corporation ( www.tearlab.com ) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The Tear Lab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning Tear Lab Osmolarity System. Headquartered in San Diego, CA, Tear Lab Corporation’s common shares trade on the NASDAQ Capital Market under the symbol ‘TEAR’ and on the Toronto Stock Exchange under the symbol ‘TLB’.
This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about Tear Lab. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual and quarterly reports on Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Tear Lab Corporation